AAV Vector Mitochondrial Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective delivery system for targeting and correcting mitochondrial DNA mutations, which accumulate with age and contribute to various diseases, as mitochondria lack nucleotide excision and recombination repair systems, and there is no established method for delivering DNA into mitochondria in living animals.
Innovation Solution
Development of mitochondrial gene-expressing viral vectors, specifically using adeno-associated virus (AAV) vectors with mitochondrial targeting sequences, to introduce nucleic acid molecules directly into mitochondria, enabling the expression of mitochondrial genes and compensation for mutated genes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional DNA delivery methods are used, then nuclear DNA can be targeted, but mitochondrial DNA cannot be delivered or corrected
Solution Approach 1:
The patent uses adeno-associated virus (AAV) as an intermediary delivery vehicle to transport nucleic acid molecules into mitochondria. The AAV vector system serves as a mediator between external therapeutic nucleic acids and the mitochondrial target, enabling delivery without requiring direct mitochondrial transfection methods. The viral capsid acts as a protective intermediary that facilitates entry through mitochondrial membranes.
Solution Approach 2:
The patent modifies the AAV vector parameters by engineering it to express mitochondrial targeting sequences (MTS) that change the vector's localization behavior. By altering the targeting parameters of the delivery system through genetic engineering of MTS incorporation, the vector is redirected from conventional nuclear delivery to mitochondrial-specific delivery, enabling mtDNA correction while maintaining the reliability of viral vector technology.
2Reliability
If mitochondrial targeting sequences are added to AAV vectors, then mitochondrial delivery is enabled, but vector complexity increases
Solution Approach 1:
The AAV vector is segmented into functional modules: the viral backbone providing essential replication and packaging functions, and the separately engineered mitochondrial targeting sequence (MTS) module that can be independently designed and inserted. This segmentation allows the MTS to be added as a discrete functional element without redesigning the entire vector system, thereby enabling mitochondrial delivery while managing complexity through modular construction.
Solution Approach 2:
The AAV vector system maintains universality by using the same basic viral architecture for both conventional and mitochondrial-targeted applications. The mitochondrial targeting capability is achieved by adding MTS to the existing proven AAV platform, allowing the same vector system to serve multiple functions - standard gene delivery and mitochondrial-specific delivery - without requiring entirely separate vector designs.
3Reliability
If nucleic acid molecules are introduced into mitochondria, then gene expression is achieved, but delivery into living animals remains unestablished
Solution Approach 1:
The patent performs preliminary action by pre-engineering the AAV vectors with mitochondrial targeting sequences and appropriate nucleic acid cargo before in vivo administration. The vectors are prepared ex vivo with all necessary components (MTS, promoter, gene of interest) already in place, eliminating the need for complex in vivo manipulation procedures. This preliminary preparation enables straightforward in vivo delivery through standard viral vector administration routes while ensuring mitochondrial targeting will occur after cellular uptake.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Nucleic acid mitochondrial delivery systems are provided. These systems are important for delivery of genetic information to a mitochondrion and for treatment of mitochondrial related diseases.